Computational Model of Heterogeneity in Melanoma: Designing Therapies and Predicting Outcomes.

ABSTRACT: Cutaneous melanoma is a highly invasive tumor and, despite the development of recent therapies, most patients with advanced metastatic melanoma have a poor clinical outcome. The most frequent mutations in melanoma affect the BRAF oncogene, a protein kinase of the MAPK signaling pathway. Therapies targeting both BRAF and MEK are effective for only 50% of patients and, almost systematically, generate drug resistance. Genetic and non-genetic mechanisms associated with the strong heterogeneity and plasticity of melanoma cells have been suggested to favor drug resistance but are still poorly understood. Recently, we have introduced a novel mathematical formalism allowing the representation of the relation between tumor heterogeneity and drug resistance and proposed several models for the develo

SUBMITTER: Hodgkinson A 

PROVIDER: S-EPMC9046868 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature